Cavan DA, Barnett AH, Leatherdale BA. Diabetic impotence: risk factors in a clinic population. Diabetes Res 1987; 5: 145-8.
[93] Hackett GI. Impotence–the most neglected complication of diabetes. Diabetes Care 1995; 28: 75-83.
[94] Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP. McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts male aging study. J Urol 2000; 163: 460-3.
[95] Reichard P, Pihl M, Rosenqvist U, Sule J. Complications in IDDM are caused by elevated blood glucose level: the Stockholm Diabetes Intervention Study (SDIS) at 10-year follow up. Diabetologia 1996; 39: 1483-8.
[96] UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
[97] Dyck PJ, Davies JL, Wilson DM, Service JF, Melton III. LJ, O'Brien PC. Risk factors for severity of diabetic polyneuropathy. Diabetes Care 1999; 22: 1479-86.
[98] Wiles PC, Pearce SM, Rice PJ, Mitchell JM. Vibration perception threshold: influence of age, height, sex, and smoking, and calculation of accurate centile values. Diabet Med 1991; 8: 157-61.
[99] Bloom S, Till S, Sonksen P, Smith S. Use of a biothesiometer to measure individual vibration thresholds and their variation in 519 non-diabetic subjects. Br Med J (Clin Res Ed) 1984; 288: 1793-5.
[100] Savage S, Estacio RO, Jeffers B, Schrier RW. Urinary albumin excretion as a predictor of diabetic retinopathy, neuropathy, and cardiovascular disease in NIDDM. Diabetes Care 1996; 19: 1243-8.
[101] Malik RA, Williamson S, Abbott C, Carrington AL, Iqbal J, Schady W, Boulton AJ. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978-81.
[102] UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. UKPDS 3BMJ 1998; 317: 703-13.
[103] Ido Y, Vindigni A, Chang K, Stramm L, Chance R, Heath WF, DiMarchi RD, Di Cera E, Williamson JR. Prevention of vascular and neural dysfunction in diabetic rats by C-peptide. Science 1997; 277: 563-6.
[104] Liao D, Sloan RP, Cascio WE, Folsom AR, Liese AD, Evans GW, Cai J, Sharrett AR. Multiple metabolic syndrome is associated with lower heart rate variability. The Atherosclerosis Risk in Communities Study. Diabetes Care 1998; 21: 2116-22.
[105] Liao D, Cai J, Brancati FL, Folsom A, Barnes RW, Tyroler HA, Heiss G. Association of vagal tone with serum insulin, glucose, and diabetes mellitus–the ARIC Study. Diabetes Res Clin Pract 1995; 30: 211-21.
[106] Dekker JM, Feskens EJM, Schouten EG, Klootwijk P, Pool J, Kromhout D. QTc duration is associated with levels of insulin and glucose tolerance. Zutphen Elderly Study. Diabetes 1996; 45: 376-80.
[107] 10Ziegler D. Diabetic cardiovascular autonomic neuropathy: prognosis, diagnosis, and treatment. Diabetes Metab Rev 1994; 10: 339-83.
[108] Gerritsen J, Dekker JM, TenVoorde BJ, Bertelsmann FW, Kostense PJ, Stehouwer CDA, Heine RJ, Nijpels G, Heethaar RM, Bouter LM. Glucose tolerance and other determinants of cardiovascular autonomic function: the Hoorn Study. Diabetologia 2000; 43: 561-70.
[109] Smulders YM, Jager A, Gerritsen J, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Cardiovascular autonomic function is associated with (micro-)alburninuria in elderly Caucasian subjects with impaired glucose tolerance or type 2 diabetes. Hoorn Study. Diabetes Care 2000; 23: 1369-74.
[110] Marre M. Genetics and the prediction of complications in type 1 diabetes. Diabetes Care 1999; 22 (Suppl 2): B53-58.
[111] Vague P, Dufayet D, Coste T, Moriscot C, Jannot MF, Raccah D. Association of diabetic neuropathy with NA/K-ATPase gene polymorphism. Diabetologia 1997; 40: 506-11.
[112] Heesom AE, Millward A, Demaine AG. Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5′ end of the aldose reductase gene. J Neurol Neurosurg Psychiatry 1998; 64: 213-6.
[113] Ichikawa F, Yamada K, Ishiyama-Shigemoto S, Yuan X, Nonaka K. Association of an (A-C)n dinucleotide repeat polymorphic marker at the 5′-region of the aldose reductase gene with retinopathy but not with nephropathy or neuropathy in Japanese patients with type 2 diabetes mellitus, Diabet Med 1999; 16: 744-8.
[114] Forsblom CM, Sane T, Groop P-H, Tötterman KJ, Kallio M, Saloranta C, Laasonen L, Summanen P, Lepäntalo M, Laatikainen L, Matikainen E, Teppo A-M, Koskimies S, Groop L. Risk factors for mortality in type II (non-insulin-dependent) diabetes: evidence of a role for neuropathy and a protective effect of HLA-DRDiabetologia 1998; 41: 1253-62.
[115] Reichard P, Pihl M. Mortality and treatment side-effects during long-term intensified conventional insulin treatment in the Stockholm Diabetes Intervention Study. Diabetes 1994; 43: 313-7.
[116] Coppini DV, Bowtell PA, Weng C, Young PJ, Sönksen PH. Showing neuropathy is related to increased mortality in diabetic patients - a survival analysis using an accelerated failure time model. J Clin Epidemiol 2000; 53: 519-23.
[117] Navarro X, Kennedy WR, Aeppli D, Sutherland DER. Neuropathy and mortality in diabetes: influence of pancreas transplantation. Muscle Nerve 1996; 19: 1009-16.
[118] Boyko EJ, Ahroni JH, Smith DG, Davignon D. Increased mortality associated with diabetic foot ulcer. Diabet Med 1996; 13: 967-72.
[119] Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. Q J Med 1980; 49: 95-108.
[120] Hasslacher C, Bässler G. Prognose der kardialen autonomen Neuropathie bei Diabetikern. Münch Med Wochenschr 1983; 125: 375-7.
[121] Navarro X, Kennedy WR, Loewenson RB, Sutherland DER. Influence of pancreas transplantation on cardiorespiratory reflexes, nerve conduction, and mortality in diabetes. Diabetes 1990; 39: 802-6.
[122] O'Brien IA, McFadden JP, Corral RJM. The influence of autonomic neuropathy on mortality in insulin-dependent diabetes. Q J Med 1991; 79: 495-502.
[123] Ewing DJ, Boland O, Neilson JMM, Cho CG, Clarke BF. Autonomic neuropathy. QT interval lengthening, and unexpected deaths in male diabetic patients. Diabetologia 1991; 34: 182-5.
[124] Jermendy G, Toth L, Vörös P, Koltai MZ, Pogatsa G. Cardiac autonomic neuropathy and QT interval length. A follow-up study in diabetic patients. Acta Cardiol 1991; 46: 189-200.
[125] Rathmann W, Ziegler D, Jahnke M, Haastert B, Cries FA. Mortality in diabetic patients with cardiovascular autonomic neuropathy. Diabet Med 1993; 10: 820-4.
[126] Luft D, Rak R, Renn W, Konz K, Eggstein M. Diabetische autonome Neuropathie: Verlauf und prognostische Bedeutung kardiovaskulärer Reflexteste. Diab Stoffw 1993; 2: 239-44.
[127] Orchard TJ, Lloyd CE, Maser RE, Kuller LH. Why does diabetic autonomic neuropathy predict IDDM mortality? An analysis from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Res Clin Pract 1996; 34 (Suppl): S165-171.
[128] Veglio M, Sivieri R, Chinaglia A, Scaglione L, Cavallo-Perin P. QT interval prolongation and mortality in type 1 diabetic patients: a 5-year cohort prospective study. Neuropathy Study Group of the Italian Society of the Study of Diabetes, Piemonte Affiliate. Diabetes Care 2000; 23: 1381-3.
[129] Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability, standards of measurement, physiological interpretation, and clinical use. Circulation 1996; 93: 1043-65.
[130]
